Form 4: Supernus Exec Sells Shares After Option Exercise

A Supernus Pharmaceuticals executive exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged trading plan.

Summary

• Frank Mottola, SVP, Chief Technology Operations Officer at Supernus Pharmaceuticals, Inc. (SUPN), engaged in pre-planned stock transactions on December 19, 2025.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 15, 2025.
• Mottola exercised options to acquire 5,000 shares of common stock at $39.40 per share.
• Concurrently, 5,000 shares were sold at a weighted average price of $50.22, with individual sales ranging from $50.00 to $50.39.
• Additionally, Mottola exercised options to acquire 15,000 shares of common stock at $25.30 per share.
• Following this, 15,000 shares were sold at a weighted average price of $50.47, with individual sales ranging from $50.00 to $50.69.
• The net effect of these transactions was no change in the total number of shares acquired and disposed of on this date, but the beneficial ownership after all reported transactions is 15,496 shares.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan, indicating planned liquidity and diversification rather than a change in sentiment.

Positives

• An executive exercised stock options, indicating the options were in-the-money and held value.
• Transactions were conducted under a pre-arranged 10b5-1 trading plan, which helps mitigate concerns about opportunistic insider trading.
• The executive realized a profit from the option exercises and subsequent sales, with sale prices significantly higher than exercise prices.

Negatives

• An executive reduced direct shareholdings by selling 20,000 shares, which could be interpreted as a reduction in direct stake, although it was part of a pre-planned strategy.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides transparency regarding insider trading activity, which can offer insights into executive compensation and personal financial planning.
• Employees: Demonstrates the value of employee stock options as a component of compensation.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request to Supernus Pharmaceuticals, Inc., any security holder of Supernus, or the staff of the Securities and Exchange Commission.

Key Dates

Recommendation

This Form 4 details routine, pre-planned insider transactions (option exercise and sale) by an executive. While the executive realized a profit, the transactions were executed under a 10b5-1 plan, suggesting a pre-determined liquidity event rather than a reaction to new information. Such a filing typically does not provide sufficient new information to alter an investment thesis, hence a 'hold' recommendation is appropriate, maintaining existing positions while awaiting more substantive company news.

Keywords

Supernus Pharmaceuticals, SUPN, Form 4, insider trading, stock options, share sale, 10b5-1 plan, executive compensation